Artikel
Bortezomib ameliorates the disease progression due to ovalbumin immunization in NZB/W F1 Lupus prone mice
Suche in Medline nach
Autoren
Veröffentlicht: | 12. September 2014 |
---|
Gliederung
Text
Background: Plasma cell depletion with bortezomib (Bz) can prevent the development of lupus nephritis and prolong survival in NZB/W mice. Here, we studied the effect of the immunization with OVA in combination with bortezomib on the disease in NZB/W mice.
Methods: NZB/W F1 female mice 16 week-old (early disease stage) were divided into 3 groups as follows: 1. Non-immunized mice as a control group, 2. Immunized mice; mice immunized with alum-precipitated OVA i.p and boosted 3 weeks after primary immunization, 3. Immunized mice as group 2 receiving two shots of bortezomib (0.75 mg/kg, i.v) at 48 and 12 hour before secondary immunization. The numbers of autoreactive anti-dsDNA antibody secreting cells (ASCs) were assessed one month after secondary immunization by ELISPOT. Parameters including anti-OVA antibody level, anti-dsDNA antibody level, proteinuria and survival rate were also analyzed.
Results: Total number of IgM anti-dsDNA ASCs in the immunized group had tendency to increase in the bone marrow and spleen compared to non-immunized, while in the group receiving Bz, they were remained comparable with non-immunized mice. Immunized NZB/W mice (group 2) developed proteinuria, which was earlier and stronger than in the non-immunized mice (group 1) and in mice additionally treated with Bz before booster immunization (group 3). Survival rate of immunized mice was reduced in comparison to the group 3 treated with Bz, while group 1 showed the longest survival. Autoantibody levels in groups 2 and 3 were higher than in group 1. This could be confirmed by analysis of anti-dsDNA antibody secreting cells in spleen and bone marrow. The Bz treatment before the secondary OVA immunization resulted in lower anti-OVA antibody levels than in immunized mice without Bz treatment.
Conclusion: Immunization with alum-precipitated OVA accelerates autoimmunity in NZB/W mice. This effect can be ameliorated by plasma cell depletion with bortezomib.